BioCentury
ARTICLE | Clinical News

Brimapitide: Ph II data

February 23, 2017 2:11 AM UTC

A double-blind, placebo-controlled, French Phase II trial in 145 patients with post-operative intraocular inflammation showed that a single 900 μg subconjunctival injection of brimapitide given at the...

BCIQ Company Profiles

Xigen S.A.

BCIQ Target Profiles

c-jun N-terminal kinase (JNK)